by Srishti Chaudhari | Jul 14, 2023 | Canadian Regulatory, Cosmetics, Natural Health Products, Research/Science/Technology
The proposed amendments to the Food and Drugs Act (FDA) in Bill C-47 mainly focus on encompassing Natural Health Products under the ‘therapeutic product’ definition, empowering the Minister of Health to have more authority to deal with therapeutic products that may...
by Delsie Braganza | Jun 21, 2023 | Canadian Quality Assurance, Canadian Regulatory, Environment and Climate Change Canada
Strengthening Environmental Protection for a Healthier Canada Act (Bill S-5), the legislation amending the Canadian Environmental Protection Act (CEPA) has been recently passed by the Senate. This bill was first introduced last year to modernize CEPA since its...
by Delsie Braganza | Jun 13, 2022 | OTC Drugs, Research/Science/Technology, U.S. Regulatory
If your company has nanomaterials in any drug (including OTC drugs) or biologic products sold in the US, this Guidance is important to you. The US Food and Drug Administration (FDA) has recently released its final industry guidance on human drug and biological...
by Delsie Braganza | Jun 13, 2022 | Canadian Regulatory, Cosmetics, Research/Science/Technology
Health Canada has been proposing amendments to the Cosmetic Regulations to introduce requirements to disclose certain fragrance allergens on the cosmetic product labels as well as amendments to enhance regulatory oversight for cosmetics. These amendments are part of...
by Sagarika Sharma | Jun 13, 2022 | Canadian Regulatory, Cosmetics, Research/Science/Technology
On June 1, 2022, Québec’s Bill 96 became law. While most of the amendments will come into force at a later date, some significant changes came into force immediately on June 1, 2022. As a result, most businesses operating in Québec will have to adjust their practices...
by Sagarika Sharma | Jun 13, 2022 | Canadian Quality Assurance, Canadian Regulatory, OTC Drugs, Research/Science/Technology
Health Canada is initiating a Pilot Program to assess the compliance of sites defined as lower risk (drugs that are not likely to generate many serious adverse drug reactions) Market Authorization Holders (MAHs). The scheduling of Good Pharmacovigilance Practices...
Recent Comments